DK167679B1 - Substituerede isoxazol-derivater, en fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende saadanne derivater - Google Patents
Substituerede isoxazol-derivater, en fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende saadanne derivater Download PDFInfo
- Publication number
- DK167679B1 DK167679B1 DK228086A DK228086A DK167679B1 DK 167679 B1 DK167679 B1 DK 167679B1 DK 228086 A DK228086 A DK 228086A DK 228086 A DK228086 A DK 228086A DK 167679 B1 DK167679 B1 DK 167679B1
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- derivatives
- formula
- substituted isoxazole
- general formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 150000002545 isoxazoles Chemical class 0.000 claims abstract description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 201000010099 disease Diseases 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 3
- -1 5- (7- (2- (4,5-dihydro-2-oxazolyl) -2-thienyl) -oxyheptyl) -3-methyl-isoxazole Chemical group 0.000 claims description 8
- 239000012024 dehydrating agents Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- PJSULAFUXXSACP-UHFFFAOYSA-N 5-[7-[5-(4,5-dihydro-1,3-oxazol-2-yl)thiophen-2-yl]oxyheptyl]-3-methyl-1,2-oxazole Chemical group O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)S1 PJSULAFUXXSACP-UHFFFAOYSA-N 0.000 claims description 3
- 230000002924 anti-infective effect Effects 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 229940121357 antivirals Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 9
- 230000000840 anti-viral effect Effects 0.000 abstract description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- VHLNLJATUHVCJE-UHFFFAOYSA-N n-(2-hydroxyethyl)-5-[7-(3-methyl-1,2-oxazol-5-yl)heptoxy]thiophene-2-carboxamide Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C(=O)NCCO)S1 VHLNLJATUHVCJE-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- AINVMTPHDUDZJT-UHFFFAOYSA-N 5-(7-chloroheptyl)-3-methyl-1,2-oxazole Chemical compound CC=1C=C(CCCCCCCCl)ON=1 AINVMTPHDUDZJT-UHFFFAOYSA-N 0.000 description 5
- 241000709661 Enterovirus Species 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- GNADIFGDFHOHCW-UHFFFAOYSA-N 5-(7-iodoheptyl)-3-methyl-1,2-oxazole Chemical compound CC=1C=C(CCCCCCCI)ON=1 GNADIFGDFHOHCW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- VKIHGEOLKYTUCP-UHFFFAOYSA-N methyl 5-[7-(3-methyl-1,2-oxazol-5-yl)heptoxy]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1OCCCCCCCC1=CC(C)=NO1 VKIHGEOLKYTUCP-UHFFFAOYSA-N 0.000 description 4
- JXLNWXSFQZMWPP-UHFFFAOYSA-N methyl 5-hydroxythiophene-2-carboxylate Chemical compound COC(=O)C1=CC=C(O)S1 JXLNWXSFQZMWPP-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QGWQUVBGUUQJHY-UHFFFAOYSA-N 5-[7-[5-(4,5-dihydro-1,3-oxazol-2-yl)thiophen-3-yl]oxyheptyl]-3-methyl-1,2-oxazole Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CSC(C=2OCCN=2)=C1 QGWQUVBGUUQJHY-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- IVSDAMUJGWUUJU-UHFFFAOYSA-N 4-[7-(3-methyl-1,2-oxazol-5-yl)heptoxy]thiophene-2-carboxylic acid Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CSC(C(O)=O)=C1 IVSDAMUJGWUUJU-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- FWHWSIDEKGSJBP-UHFFFAOYSA-N methyl 4-hydroxythiophene-2-carboxylate Chemical compound COC(=O)C1=CC(O)=CS1 FWHWSIDEKGSJBP-UHFFFAOYSA-N 0.000 description 2
- YWOCPLCLKUUPHB-UHFFFAOYSA-N n-(2-hydroxyethyl)-4-[7-(3-methyl-1,2-oxazol-5-yl)heptoxy]thiophene-2-carboxamide Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CSC(C(=O)NCCO)=C1 YWOCPLCLKUUPHB-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- FICAQKBMCKEFDI-UHFFFAOYSA-N 3,5-dimethyl-1,2-oxazole Chemical compound CC=1C=C(C)ON=1 FICAQKBMCKEFDI-UHFFFAOYSA-N 0.000 description 1
- FFIUBSLJPHJUCZ-UHFFFAOYSA-N 4-hydroxythiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC(O)=CS1 FFIUBSLJPHJUCZ-UHFFFAOYSA-N 0.000 description 1
- WBWVCVIGPNKPAT-UHFFFAOYSA-N 5-[7-(3-methyl-1,2-oxazol-5-yl)heptoxy]thiophene-2-carboxylic acid Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C(O)=O)S1 WBWVCVIGPNKPAT-UHFFFAOYSA-N 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101001018147 Homo sapiens Mitogen-activated protein kinase kinase kinase 4 Proteins 0.000 description 1
- 102100033060 Mitogen-activated protein kinase kinase kinase 4 Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical class CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- LQOXZBKAAJDINZ-UHFFFAOYSA-N methyl 4-[7-(3-methyl-1,2-oxazol-5-yl)heptoxy]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC(OCCCCCCCC=2ON=C(C)C=2)=C1 LQOXZBKAAJDINZ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT149385 | 1985-05-17 | ||
| AT149385 | 1985-05-17 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK228086D0 DK228086D0 (da) | 1986-05-16 |
| DK228086A DK228086A (da) | 1986-11-18 |
| DK167679B1 true DK167679B1 (da) | 1993-12-06 |
Family
ID=3515076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK228086A DK167679B1 (da) | 1985-05-17 | 1986-05-16 | Substituerede isoxazol-derivater, en fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende saadanne derivater |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4812472A (cs) |
| EP (1) | EP0211157B1 (cs) |
| JP (1) | JPH0680059B2 (cs) |
| KR (1) | KR930006776B1 (cs) |
| AT (1) | ATE59647T1 (cs) |
| AU (1) | AU588315B2 (cs) |
| CA (1) | CA1271481A (cs) |
| CS (1) | CS254349B2 (cs) |
| DD (1) | DD258812A1 (cs) |
| DE (1) | DE3676378D1 (cs) |
| DK (1) | DK167679B1 (cs) |
| ES (1) | ES8801805A1 (cs) |
| FI (1) | FI83782C (cs) |
| HU (1) | HU197003B (cs) |
| NO (1) | NO164352C (cs) |
| NZ (1) | NZ216125A (cs) |
| SG (1) | SG43191G (cs) |
| SU (1) | SU1493106A3 (cs) |
| UA (1) | UA5548A1 (cs) |
| ZA (1) | ZA863652B (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861791A (en) * | 1983-08-29 | 1989-08-29 | Sterling Drug Inc. | Dihydro-oxazolyl substituted-phenyl-aliphatic lower alkyl and their use as antiviral agents |
| MY102282A (en) * | 1987-01-28 | 1992-05-15 | Cl Pharma | Isoxazole derivatives with antiviral activities and pharmaceutical products containing these. |
| GB8911158D0 (en) * | 1989-05-16 | 1989-07-05 | Janssen Pharmaceutica Nv | Antiviral pyridazinamines |
| US5070090A (en) * | 1989-05-15 | 1991-12-03 | Janssen Pharmaceutica N.V. | Antipicorpaviral herterocyclic-substituted morpholinyl alkylphenol ethers |
| JP2001522848A (ja) * | 1997-11-07 | 2001-11-20 | アメリカン・サイアナミド・カンパニー | 除草性フラニル−およびチエニルオキシアジン |
| CN116196752A (zh) * | 2023-02-22 | 2023-06-02 | 吴桥县六合德利化工有限责任公司 | 一种利用氯化亚砜为原料生产ob酸的尾气处理工艺 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2714082A (en) * | 1955-07-26 | New oxazoline derivatives | ||
| US4451476A (en) * | 1982-12-13 | 1984-05-29 | Sterling Drug Inc. | Isoxazoles as antiviral agents |
| NZ209209A (en) * | 1983-08-29 | 1988-02-12 | Sterling Drug Inc | Substituted phenyl-aliphatic isoxazole derivatives and pharmaceutical compositions |
-
1986
- 1986-05-09 FI FI861934A patent/FI83782C/fi not_active IP Right Cessation
- 1986-05-12 NZ NZ216125A patent/NZ216125A/xx unknown
- 1986-05-13 CA CA000508965A patent/CA1271481A/en not_active Expired - Fee Related
- 1986-05-13 DD DD86290190A patent/DD258812A1/de not_active IP Right Cessation
- 1986-05-14 AT AT86106529T patent/ATE59647T1/de not_active IP Right Cessation
- 1986-05-14 NO NO861923A patent/NO164352C/no unknown
- 1986-05-14 EP EP86106529A patent/EP0211157B1/de not_active Expired - Lifetime
- 1986-05-14 DE DE8686106529T patent/DE3676378D1/de not_active Expired - Fee Related
- 1986-05-15 KR KR1019860003792A patent/KR930006776B1/ko not_active Expired - Fee Related
- 1986-05-16 ES ES555030A patent/ES8801805A1/es not_active Expired
- 1986-05-16 CS CS863572A patent/CS254349B2/cs unknown
- 1986-05-16 ZA ZA863652A patent/ZA863652B/xx unknown
- 1986-05-16 DK DK228086A patent/DK167679B1/da not_active Application Discontinuation
- 1986-05-16 SU SU864027501A patent/SU1493106A3/ru active
- 1986-05-16 AU AU57508/86A patent/AU588315B2/en not_active Ceased
- 1986-05-16 HU HU862078A patent/HU197003B/hu not_active IP Right Cessation
- 1986-05-16 UA UA4027501A patent/UA5548A1/uk unknown
- 1986-05-16 JP JP61110975A patent/JPH0680059B2/ja not_active Expired - Lifetime
-
1987
- 1987-11-12 US US07/120,264 patent/US4812472A/en not_active Expired - Fee Related
-
1991
- 1991-06-11 SG SG43191A patent/SG43191G/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR860009011A (ko) | 1986-12-19 |
| ES555030A0 (es) | 1987-07-16 |
| US4812472A (en) | 1989-03-14 |
| NO164352B (no) | 1990-06-18 |
| FI83782B (fi) | 1991-05-15 |
| NZ216125A (en) | 1988-10-28 |
| FI861934A0 (fi) | 1986-05-09 |
| DK228086D0 (da) | 1986-05-16 |
| EP0211157B1 (de) | 1991-01-02 |
| AU5750886A (en) | 1986-11-20 |
| NO164352C (no) | 1990-09-26 |
| JPS61268680A (ja) | 1986-11-28 |
| CS254349B2 (en) | 1988-01-15 |
| AU588315B2 (en) | 1989-09-14 |
| FI83782C (fi) | 1991-08-26 |
| SU1493106A3 (ru) | 1989-07-07 |
| DE3676378D1 (de) | 1991-02-07 |
| KR930006776B1 (ko) | 1993-07-23 |
| ZA863652B (en) | 1987-01-28 |
| JPH0680059B2 (ja) | 1994-10-12 |
| EP0211157A1 (de) | 1987-02-25 |
| UA5548A1 (uk) | 1994-12-28 |
| NO861923L (no) | 1986-11-18 |
| DK228086A (da) | 1986-11-18 |
| SG43191G (en) | 1991-08-23 |
| DD258812A1 (de) | 1988-08-03 |
| CA1271481A (en) | 1990-07-10 |
| FI861934L (fi) | 1986-11-18 |
| HU197003B (en) | 1989-02-28 |
| HUT43594A (en) | 1987-11-30 |
| ES8801805A1 (es) | 1987-07-16 |
| ATE59647T1 (de) | 1991-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2183632C2 (ru) | Антагонисты эндотелина: n-[[2'-[[(4,5-диметил-3-изоксазолил)амино]сульфонил]-4-(2-оксазолил)[1,1'- бифенил]-2-ил]метил]-n,3,3-триметилбутанамид и n-(4,5-диметил-3-изоксазолил)-2'-[(3,3-диметил-2-оксо-1-пирролидинил)метил ]-4'-(2-оксазолил)[1,1'-бифенил]-2-сульфонамид и их соли | |
| RU2116301C1 (ru) | Сульфонамидное производное изоксазола или его фармацевтически приемлемая соль | |
| EP2683697B1 (en) | Substituted morpholines as modulators for the calcium sensing receptor | |
| CZ20022293A3 (cs) | Sulfonamidy a jejich deriváty, které upravují aktivitu endothelinu | |
| Zhao et al. | Discovery of novel phenoxypyridine as promising protoporphyrinogen IX oxidase inhibitors | |
| DK167679B1 (da) | Substituerede isoxazol-derivater, en fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende saadanne derivater | |
| DK163580B (da) | Analogifremgangsmaade til fremstilling af cyclohexancarboxylsyrederivater | |
| DK168010B1 (da) | Tetrahydroisoquinolinforbindelser og farmaceutisk middel indeholdende en saadan forbindelse | |
| KR900006118B1 (ko) | 4-퀴놀론 유도체의 제법 | |
| KR20040034804A (ko) | 신규 엔-하이드록시 티오우레아, 우레아 및 아미드계화합물 및 이를 함유하는 약제학적 조성물 | |
| AU583847B2 (en) | Use of 4-(isoxazolyl)-thiazole-2-oxamic acid derivatives | |
| DK170047B1 (da) | Med basiske heterocycliske grupper substituerede 5-halogen-thienoisothiazol-3(2H)-on-1,1-dioxider og salte deraf, fremgangsmåde til fremstilling af sådanne forbindelser, farmaceutiske præparater indeholdende disse forbindelser og forbindelsernes anvendelse ved fremstilling af lægemidler til behandling af angsttilstande | |
| FR2565980A1 (fr) | Nouveaux esters de 1,1-dioxydes de n-heteroaryl-4-hydroxy-2-methyl- 2h -1,2-benzothiazine- (ou thieno(2,3-e)-1,2-thiazine)-3-carboxamide precurseurs de medicaments et composition pharmaceutiques les contenant | |
| US4841065A (en) | Isoxazole derivatives with antiviral activities and pharmaceutical products containing these | |
| JPH0240648B2 (ja) | Ketsushobankatsuseiinshokuseizai | |
| DK163732B (da) | N-oe2-oeoe5-(aminomethyl)-2-fyranylaamethylthioaa-ethylaa-2-nitro-1,1-ethen-diaminderivater, fremgangsmaade til deres fremstilling og anvendelse af derivaterne til fremstilling af laegemidler | |
| FR2542741A1 (fr) | 3,4-diamino-1,2,5-thiadiazoles substitues possedant une activite antagoniste du recepteur-h2 de l'histamine | |
| JP2535528B2 (ja) | 〔２−（１，３−ベンゾジオキソ−ル−５−イル）エチル〕チオ誘導体 | |
| JPH01143877A (ja) | スタウロスポリン誘導体 | |
| EP0668276A1 (en) | 2-alkoxy-5,6,7,8-tetrahydroquinoxaline derivative, process for producing the same, and use thereof | |
| KR20020025091A (ko) | 벤즈 이미다졸 화합물 및 그것을 함유하는 의약 | |
| FI87780B (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 2-tienyloxiaettiksyraderivat | |
| JPH0121143B2 (cs) | ||
| NO881280L (no) | Nye tieno-imidazo(2,1-b)tiazolderivater, fremgangsmaate til deres fremstilling og farmasoeytiske preparater som inneholder dem. | |
| JPH01156974A (ja) | ベンゾジオキソール誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHB | Application shelved due to non-payment |